The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced
stage solid tumors has become the standard of care in several instances, particularly for …

Antiangiogenic therapy has now become a cornerstone in the treatment of several solid
tumor cancers. Those drugs present with a renal toxicity profile manifesting as proteinuria …

Angiogenesis has become an innovative target in cancer therapy. Agents that inhibit
vascular endothelial growth factor (VEGF), one of the most potent promoters of …

Abstract One Von Hippel-Lindau (VHL) tumor suppressor gene is lost in most renal cell
carcinomas while the nondeleted allele exhibits hypermethylation-induced inactivation or …

Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an
important part of standard therapy in multiple cancer indications. With expanded clinical …

Recently, cancer therapies have been supplemented by vascular endothelial growth factor
(VEGF) inhibitors as anti-angiogenic agents. However, kidney-related adverse reactions …

BACKGROUND VEGF signaling pathway inhibitor (anti‐VEGF) therapy is associated with
hypertension, but little is known about predisposing clinical characteristics. This study …

Bevacizumab, a recombinant humanized monoclonal antibody targeting the vascular
endothelial growth factor (VEGF), has been approved in the US as first-and second-line …

Renal cell carcinoma is a highly vascular tumor associated with expression of vascular
endothelial growth factor (VEGF). Recently, VEGF-targeted therapies have been identified …

Angiogenesis inhibitors that target the epidermal growth factor (EGF) receptor (EGFR) and
vascular endothelial growth factor (VEGF) constitute an important addition to the therapeutic …